PharmaForceIQ, an independent provider of precision customer engagement technologies for the life sciences industry, has reported significant growth over the past year, with a sharp rise in average contract value and expansion across several key client portfolios.

In one example, the company grew a single pilot campaign into a full-scale engagement across an entire specialty pharmaceutical portfolio in under eight months. It also reports a 100% client renewal rate — an indicator, it says, of the performance and reliability of its optichannel engagement model.

The shift from omnichannel to optichannel reflects a broader industry trend: replacing one-size-fits-all campaign models with data-driven, hyper-personalised engagement, continually refined through real-time feedback loops.

“Technology now allows teams to tailor outreach based on real-world behaviour, preferences, and performance across channels,” said Stephen Onikoro, chief operating officer at PharmaForceIQ. “Optichannel helps ensure investments are focused on what works — for each audience, in each moment.”

Chief strategy officer Hemal Somaiya is one of the voices leading the shift. Recognised as a 2025 MM+M Woman of Distinction and a PM360 ELITE ‘Disrupter’, Somaiya believes smarter campaign design is critical to both efficiency and impact.

“It’s about creating value — not more noise,” she said. “Optichannel engagement can personalise content, improve marketing ROI, and ultimately support better health outcomes by connecting with healthcare professionals and patients in more meaningful ways.”

PharmaForceIQ offers analytics-led campaign design, adaptive targeting, and real-time channel optimisation, using AI and machine learning tools to guide engagement strategies.